- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02206555
PrEP Demonstration Project (PRELUDE Study) (PRELUDE)
Implementation of HIV Preexposure Prophylaxis With Antiretroviral Medications Among People at High Risk for HIV Infection: A Demonstration Project
Significant increases in HIV diagnoses among gay and other homosexually active men, in Australia and internationally, have been observed since the late 1990s. The levels of high HIV risk sexual practices among gay men have also increased, particularly unprotected anal intercourse (UAI). Nationally, over three quarters of the new HIV infections diagnosed annually are among men who have sex with men (MSM). The proportion of heterosexual men and women among those diagnosed with HIV annually has also increased in recent years. Despite successes in some situations, HIV transmission has not been adequately reduced by the prevention methods available to those at risk, such as education, condoms, and treatment of sexually transmitted infections (STIs).
The effectiveness of daily oral antiretroviral medications (ARVs) as preexposure prophylaxis of HIV (PrEP) has now been established by clinical trials in both heterosexual adults and homosexual men. Whether PrEP confers high rates of protection in real life situations and is a feasible strategy to implement still requires further investigation. Through its "HIV prevention strategy 2015: New era," NSW Health committed to consider how to most appropriately and efficiently implement PrEP in line with evidence. This commitment translated in the support to this PrEP demonstration project.
This demonstration project is designed to evaluate the off-label provision of daily combination of tenofovir disoproxil fumarate and emtricitabine (TDF/FTC, known as TRUVADA) as PrEP to a sample of sero-negative individuals at high risk for HIV infection in clinical settings in New South Wales. The project will inform policy development regarding primary HIV prevention with PrEP.
This is an open-label, single-arm treatment evaluation study. All consenting and eligible HIV negative participants will receive TRUVADA prescribed for daily administration orally. At each followup visit, the following procedures will be conducted: clinical evaluations/ procedures, laboratory evaluations/ procedures, testing for HIV, STIs, hepatic and renal function, assessment for adherence to the prescribed medication, side effects, eligibility for next TRUVADA prescription, and willingness to continue on PrEP.
As a study requirement, participants will be offered a self-administered assessment of behaviour, lifestyle and attitudes which will be conducted ideally within two and no more than seven days of the clinic visit in the participant's private space.
Analyses will include: the feasibility of PrEP delivery, adherence to the study medication, safety and tolerability, the effects of PrEP use on behavior, and statistical analyses of the risk of HIV seroconversion.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 4
Contactos e Locais
Locais de estudo
-
-
New South Wales
-
Camperdown, New South Wales, Austrália, 2050
- RPA Sexual Health
-
Darlinghurst, New South Wales, Austrália, 2010
- Holdsworth House Medical Practice
-
Darlinghurst, New South Wales, Austrália, 2010
- St Vincent's Hospital HIV, Immunology and Infectious Disease Unit
-
Parramatta, New South Wales, Austrália, 2150
- Western Sydney Sexual Health Centre
-
Sydney, New South Wales, Austrália, 2000
- Sydney Sexual Health Centre
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- HIV negative at enrollment (per algorithm provided in protocol)
- At high and ongoing risk for acquiring HIV infection (per algorithm provided in protocol)
- Aged 18 years or over
- Resident of NSW (or elsewhere in Australia if they visit NSW with sufficient frequency to allow participation)
- Medicare eligible (to have Medicare coverage for the standard-of-care services)
- Willing and able to provide informed consent
- Willing and able to take part in all required study procedures
- Proficiency in written and spoken English (necessary to complete attitude, behavioural and lifestyle surveys)
Exclusion Criteria:
- HIV-1 infected or has symptoms consistent with acute viral infection (If HIV positive status is not confirmed by testing, delay starting PrEP for at least one month and reconfirm negative HIV-1 status).
- Having an estimated creatinine clearance (glomerular filtration rate [GFR]) <60ml/min
- Having or developing clinical symptoms suggestive of lactic acidosis or pronounced hepatotoxicity (including nausea, vomiting, unusual or unexpected stomach discomfort, and weakness)
- Concurrently taking a nephrotoxic agent (e.g., high-dose non-steroidal anti-inflammatory drugs / NSAIDs)
- Allergic to tenofovir disoproxil fumarate and/or emtricitabine (based on self-report or recorded)
- Concurrently taking prescribed products containing emtricitabine or tenofovir disoproxil fumarate including ATRIPLA®, COMPLERA®, EMTRIVA, STRIBILD®, VIREAD; other drugs containing lamivudine; HEPSERA
- Mental health issues, memory loss or other cognitive impairment or intellectual disability that may compromise participant safety and/or regimen adherence
- Factors or conditions that may compromise a participant's retention in the study (incarceration, planned relocation or potential absence from NSW for a period of 3 months or longer during the course of the study)
- Unwilling to adhere to any of the required study procedures
- Currently breastfeeding
Note: Safety for infants exposed to TRUVADA during pregnancy is not fully assessed but no harm has been reported. Therefore, planning to become pregnant or currently being pregnant is not an exclusion criterion for this study. However, women who are pregnant should learn about the risks and benefits of TRUVADA to reduce the risk of acquiring HIV during their pregnancy. Site investigators will review the risks and benefits of TRUVADA and of potential HIV infection with pregnant women and women who plan to become pregnant.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Treatment group (TRUVADA)
Homosexual men and heterosexual men and women at high risk of HIV infection
|
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Time to accrual
Prazo: Approximately 18 months
|
Time to accrual of 300 person-years of follow-up on TRUVADA.
Each participant will receive TRUVADA for a maximum of 12 months, and will be followed for an additional three months after discontinuation.
(Primary endpoint: feasibility of the process of PrEP delivery in health care settings in NSW)
|
Approximately 18 months
|
Seroconversion-free time on PrEP
Prazo: Approximately 18 months
|
Seroconversion-free time on PrEP (Primary endpoint: feasibility of the process of PrEP delivery in health care settings in NSW)
|
Approximately 18 months
|
Time to TRUVADA discontinuation
Prazo: Approximately 18 months
|
Time to TRUVADA discontinuation (primary endpoint: adherence)
|
Approximately 18 months
|
Prescribed doses taken
Prazo: Approximately 18 months
|
Percentage of prescribed doses taken orally in the prescribed period (primary endpoint: adherence)
|
Approximately 18 months
|
Incidents of HIV seroconversion
Prazo: Approximately 24 months
|
Incidence of HIV seroconversion among study participants during the course of their study participation and in six months following PrEP discontinuation (primary endpoint: safety and side effects)
|
Approximately 24 months
|
Incidents of rectal gonorrhea and chlamydia
Prazo: Approximately 18 months
|
New rectal gonorrhoea and chlamydia infections (primary endpoint: behavioral effects of PrEP use)
|
Approximately 18 months
|
Serious adverse reactions
Prazo: Approximately 18 months
|
(primary endpoint: safety and side effects)
|
Approximately 18 months
|
Adverse events
Prazo: Approximately 18 months
|
Any adverse events leading to interruption or discontinuation of the study product (TRUVADA) (primary endpoint: safety and side effects)
|
Approximately 18 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Cadeira de estudo: Iryna Zablotska, MD, MPH, PhD, The Kirby Institute for Infection and Immunity in Society
Publicações e links úteis
Publicações Gerais
- Vaccher SJ, Marzinke MA, Templeton DJ, Haire BG, Ryder N, McNulty A, Foster R, Grulich AE, Zablotska IB; PRELUDE Study Team; NSW HIV Prevention Partnership Project. Predictors of Daily Adherence to HIV Pre-exposure Prophylaxis in Gay/Bisexual Men in the PRELUDE Demonstration Project. AIDS Behav. 2019 May;23(5):1287-1296. doi: 10.1007/s10461-018-2353-5.
- Vaccher SJ, Gianacas C, Templeton DJ, Poynten IM, Haire BG, Ooi C, Foster R, McNulty A, Grulich AE, Zablotska IB; PRELUDE Study Team. Baseline Preferences for Daily, Event-Driven, or Periodic HIV Pre-Exposure Prophylaxis among Gay and Bisexual Men in the PRELUDE Demonstration Project. Front Public Health. 2017 Dec 15;5:341. doi: 10.3389/fpubh.2017.00341. eCollection 2017.
- Vaccher S, Grulich A, McAllister J, Templeton DJ, Bloch M, McNulty A, Holden J, Poynten IM, Prestage G, Zablotska I; PRELUDE Study Team. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE. BMJ Open. 2016 Jun 20;6(6):e012179. doi: 10.1136/bmjopen-2016-012179. Erratum In: BMJ Open. 2016 Jun 27;6(6):e012179corr1.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Mecanismos Moleculares de Ação Farmacológica
- Agentes Anti-Infecciosos
- Antivirais
- Inibidores da transcriptase reversa
- Inibidores da Síntese de Ácido Nucleico
- Inibidores Enzimáticos
- Agentes anti-HIV
- Antirretrovirais
- Tenofovir
- Emtricitabina
- Emtricitabina, Fumarato de Tenofovir Disoproxil Combinação de Medicamentos
Outros números de identificação do estudo
- HEPP 1403
- 14/098 (Outro identificador: St Vincent's Hospital HREC)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecrutamentoHIV | Teste de HIV | Ligação do HIV ao Cuidado | Tratamento de HIVEstados Unidos
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement e outros colaboradoresDesconhecidoHIV | Crianças não infectadas pelo HIV | Crianças expostas ao HIVCamarões
-
University of MinnesotaRetiradoInfecções por HIV | HIV/AIDS | HIV | AUXILIA | Aids/problema de HIV | AIDS e InfecçõesEstados Unidos
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationConcluídoTeste de HIV do parceiro | Aconselhamento de casal HIV | Comunicação de casal | Incidência de HIVCamarões, República Dominicana, Geórgia, Índia
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... e outros colaboradoresRecrutamentoHIV | Teste de HIV | Vinculação ao cuidadoÁfrica do Sul
-
CDC FoundationGilead SciencesDesconhecidoProfilaxia pré-exposição ao HIV | Quimioprofilaxia HIVEstados Unidos
-
Erasmus Medical CenterAinda não está recrutandoInfecções por HIV | HIV | Infecção por HIV-1 | Infecção HIV IHolanda
-
Helios SaludViiV HealthcareDesconhecidoHIV | Infecção por HIV-1Argentina
-
National Taiwan UniversityRecrutamento
-
University of Maryland, BaltimoreRetiradoHIV | Transplante de rim | Reservatório de HIV | CCR5Estados Unidos
Ensaios clínicos em emtricitabine/tenofovir disoproxil fumarate
-
National Institute of Allergy and Infectious Diseases...Microbicide Trials NetworkConcluídoInfecções por HIVÁfrica do Sul, Uganda, Zimbábue
-
National Institute of Allergy and Infectious Diseases...Microbicide Trials NetworkConcluídoInfecções por HIVZimbábue, Uganda
-
CONRADEastern Virginia Medical School; University of North Carolina; Agility Clinical...Concluído
-
Samjin Pharmaceutical Co., Ltd.Concluído
-
Yale UniversityNational Heart, Lung, and Blood Institute (NHLBI)RecrutamentoInsuficiência Cardíaca DescompensadaEstados Unidos
-
University of WashingtonBill and Melinda Gates FoundationConcluídoInfecções por HIV | Infecções por HIV-1Quênia, Uganda
-
Samjin Pharmaceutical Co., Ltd.Concluído
-
Vanderbilt University Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)ConcluídoSaudávelEstados Unidos
-
Daewoong Pharmaceutical Co. LTD.C&R Research, Inc.ConcluídoHepatite B CrônicaRepublica da Coréia
-
Merck Sharp & Dohme LLCAtivo, não recrutandoProfilaxia | Vírus da Imunodeficiência Humana Tipo 1 | HIV-1Estados Unidos, África do Sul, Uganda